Johnson & Johnson
JNJ- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000200406
In the last 90 days, Johnson & Johnson insiders filed 0 open-market purchases and 3 sales; 4,720 institutions reported holding it in 13F filings for Q2 2026, worth $457.0B in total; 5 superinvestors hold it, including Markel Group and Fairfax Financial.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Johnson & Johnson insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $45.4M in total
- Insiders trading
- 3
- Net value
- −$45.4M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Johnson & Johnson, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pinto Daniel E | Director | – | Sep 10, 2026 | 5 |
| Woods Eugene A. | Director | – | Sep 10, 2026 | 5 |
| Hewson Marillyn A | Director | – | Sep 10, 2026 | 5 |
| Schmid Timothy | EVP, WW Chair, MedTech | 25,447 | Sep 4, 2026 | 5 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 194,451 | Aug 18, 2026 | 3 |
| Duato Joaquin | CEO and Chairman of the Board | 275,967 | Aug 14, 2026 | 5 |
| Forminard Elizabeth | EVP, Chief Legal Officer | 16,994 | Aug 7, 2026 | 4 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | 23,003 | Jul 21, 2026 | 3 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | 114,288 | Jun 12, 2026 | 4 |
| Reed John C | EVP, Innovative Medicine, R&D | 24,911 | May 4, 2026 | 2 |
| Morikis John G | Director | 1,849 | Apr 27, 2026 | 2 |
| Johnson Paula A | Director | – | Apr 27, 2026 | 1 |
| Joly Hubert | Director | – | Apr 27, 2026 | 1 |
| Beckerle Mary C | Director | – | Apr 27, 2026 | 1 |
| McClellan Mark B. | Director | – | Apr 27, 2026 | 1 |
| Doudna Jennifer A | Director | – | Apr 27, 2026 | 1 |
| Weinberger Mark A | Director | 1,000 | Apr 27, 2026 | 1 |
| West Nadja | Director | – | Apr 27, 2026 | 1 |
| Decker Robert J | VP Corporate Controller | 23,682 | Mar 3, 2026 | 3 |
| Wolk Joseph J | Exec VP, CFO | 14,000 | Feb 18, 2026 | 2 |
| Swanson James D. | EVP, CIO | 25,698 | Feb 18, 2026 | 2 |
| Mulholland Kristen | EVP, Chief HR Officer | 19,830 | Feb 18, 2026 | 3 |
| Davis D Scott | Director | – | Oct 15, 2024 | 0 |
| Mulcahy Anne M | Director | – | Apr 29, 2024 | 0 |
| Adamczyk Darius | Director | – | Apr 29, 2024 | 0 |
| Fasolo Peter | Exec VP, Chief HR Officer | 112,076 | Feb 20, 2024 | 0 |
| Hait William | EVP, Chief EI and Med Officer | 38,647 | Feb 20, 2024 | 0 |
| McEvoy Ashley | EVP, WW Chair, MedTech | 52,038 | Aug 25, 2023 | 0 |
| Washington A. Eugene | Director | – | Mar 9, 2023 | 0 |
| Mongon Thibaut | Exec VP, WW Chair, Cons Health | 65,915 | Feb 15, 2023 | 0 |
| Gorsky Alex | Director | 766,584 | Jan 18, 2023 | 0 |
| Williams Ronald A | Director | – | Feb 17, 2022 | 0 |
| Prince Charles | Director | – | Feb 17, 2022 | 0 |
| Mammen Mathai | EVP, Pharm, R&D | 41,934 | Feb 17, 2022 | 0 |
| Davis Ian | Director | – | Feb 17, 2022 | 0 |
| Ullmann Michael H | Exec VP, General Counsel | 158,835 | Feb 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)9:08 AM ET | Sep 2 | 2 days | Schmid TimothyEVP, WW Chair, MedTech | SSale | −33.6K | $274.74 | −$9.23M | −56.9%25.4K after | 2 lots |
| Aug 18, 2026 (view filing)6:31 PM ET | Aug 17 | 1 day | Taubert Jennifer LEVP, WWC. Innovative Medicine | SSale | −15.0K | $263.36 | −$3.95M | −7.2%194.5K after | |
| Aug 14, 2026 (view filing)4:35 PM ET | Aug 13 | 1 day | Duato JoaquinCEO and Chairman of the Board | SSale | −123.3K | $261.17 | −$32.2M | −30.9%276.0K after | 2 lots |
| Aug 7, 2026 (view filing)5:50 PM ET | Aug 5 | 2 days | Duato JoaquinCEO and Chairman of the Board | SSale | −48.5K | $258.15 | −$12.5M | −14.9%276.0K after | 2 lots |
| Aug 7, 2026 (view filing)5:44 PM ET | Aug 6 | 1 day | Forminard ElizabethEVP, Chief Legal Officer | SSale | −15.9K | $257.00 | −$4.09M | −48.4%17.0K after | 2 lots |
| Jul 21, 2026 (view filing)5:27 PM ET | Jul 20 | 1 day | Broadhurst VanessaEVP, Global Corp Affairs | SSale | −23.1K | $251.27 | −$5.79M | −50.1%23.0K after | |
| Jun 12, 2026 (view filing) | Jun 11 | 1 day | Wengel Kathryn EEVP, Chief TO and Risk Officer | SSale | −10.0K | $241.15 | −$2.41M | −8.0%114.3K after | |
| Mar 3, 2026 (view filing) | Feb 27 | 4 days | Decker Robert JVP Corporate Controller | SSale | −4.08K | $247.87 | −$1.01M | −14.7%23.7K after | |
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Schmid TimothyEVP, WW Chair, MedTech | SSale | −1.32K | $245.66 | −$324.8K | −4.9%25.4K after | |
| Feb 18, 2026 (view filing) | Feb 13-17 | 5 days | Swanson James D.EVP, CIO | SSale | −62.1K | $243.39 | −$15.1M | −70.7%25.7K after | 3 lots |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Wolk Joseph JExec VP, CFO | SSale | −89.7K | $242.80 | −$21.8M | −86.5%14.0K after | 4 lots |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Reed John CEVP, Innovative Medicine, R&D | SSale | −53.9K | $243.00 | −$13.1M | −83.5%10.7K after | 3 lots |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Schmid TimothyEVP, WW Chair, MedTech | SSale | −22.6K | $244.33 | −$5.53M | −45.8%26.8K after | 2 lots |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Broadhurst VanessaEVP, Global Corp Affairs | SSale | −6.20K | $243.39 | −$1.51M | −21.2%23.0K after | |
| Jan 28, 2026 (view filing) | Jan 26 | 2 days | Duato JoaquinCEO and Chairman of the Board | SSale | −100.0K | $221.23 | −$22.1M | −76.4%30.9K after | 2 lots |
| Dec 1, 2025 (view filing) | Nov 26 | 5 days | Morikis John GDirector | PPurchase | +1.25K | $206.15 | +$257.7K | +208.9%1.85K after | |
| Oct 20, 2025 (view filing) | Oct 17 | 3 days | Reed John CEVP, Innovative Medicine, R&D | SSale | −21.7K | $192.71 | −$4.19M | −67.1%10.7K after | |
| Sep 5, 2025 (view filing) | Sep 4 | 1 day | Taubert Jennifer LEVP, WWC. Innovative Medicine | SSale | −56.5K | $177.81 | −$10.0M | −24.1%178.0K after | |
| Aug 25, 2025 (view filing) | Aug 22 | 3 days | Duato JoaquinCEO and Chairman of the Board | SSale | −125.8K | $179.21 | −$22.5M | −31.3%276.0K after | |
| Aug 18, 2025 (view filing) | Aug 15 | 3 days | Wolk Joseph JExec VP, CFO | SSale | −16.8K | $176.91 | −$2.98M | −54.6%14.0K after | |
| Jul 18, 2025 (view filing) | Jul 17 | 1 day | Reed John CEVP, Innovative Medicine, R&D | SSale | −19.1K | $163.55 | −$3.13M | −64.2%10.7K after | |
| Feb 26, 2025 (view filing) | Feb 25 | 1 day | Decker Robert JVP Corporate Controller | SSale | −7.00K | $165.88 | −$1.16M | −25.0%21.0K after | |
| Feb 18, 2025 (view filing) | Feb 18 | Same day | Schmid TimothyEVP, WW Chair, MedTech | SSale | −403 | $156.15 | −$62.9K | −2.6%15.1K after | |
| Feb 11, 2025 (view filing) | Feb 7 | 4 days | Wolk Joseph JExec VP, CFO | SSale | −13.0K | $153.89 | −$2.00M | −100.0%0 after | |
| Dec 12, 2024 (view filing) | Dec 12 | Same day | Weinberger Mark ADirector | PPurchase | +1.00K | $147.22 | +$147.2K | New position1.00K after | |
| Sep 3, 2024 (view filing) | Aug 30 | 4 days | Decker Robert JVP Corporate Controller | SSale | −5.63K | $165.06 | −$930.1K | −22.9%19.0K after | |
| Mar 13, 2024 (view filing) | Mar 13 | Same day | Broadhurst VanessaEVP, Global Corp Affairs | SSale | −8.89K | $162.16 | −$1.44M | −37.1%15.0K after | |
| Feb 12, 2024 (view filing) | Feb 9 | 3 days | Taubert Jennifer LEVP, WW Chair, Pharmaceuticals | SSale | −59.4K | $156.27 | −$9.28M | −29.6%141.4K after | |
| Jul 27, 2023 (view filing) | Jul 25 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −20.0K | $170.32 | −$3.41M | −16.3%102.7K after | |
| Jul 27, 2023 (view filing) | Jul 26 | 1 day | Hait WilliamSee Remarks | SSale | −14.7K | $172.00 | −$2.53M | −14.3%87.7K after | |
| Jun 14, 2023 (view filing) | Jun 12 | 2 days | Wengel Kathryn EEVP, Chief TO and Risk Officer | SSale | −12.5K | $160.00 | −$1.99M | −15.9%65.9K after | |
| Mar 8, 2023 (view filing) | Mar 6 | 2 days | Swanson James D.See Remarks | SSale | −1.06K | $154.66 | −$164.2K | −10.3%9.22K after | |
| Dec 15, 2022 (view filing) | Dec 13 | 2 days | Wolk Joseph JExec VP, CFO | SSale | −14.8K | $179.60 | −$2.65M | −29.2%35.8K after | 2 lots |
| Dec 2, 2022 (view filing) | Nov 30 | 2 days | McEvoy AshleyEVP, WW Chair, MedTech | SSale | −73.3K | $175.47 | −$12.9M | −63.7%41.8K after | 2 lots |
| Nov 23, 2022 (view filing) | Nov 22 | 1 day | Taubert Jennifer LEVP, WW Chair, Pharmaceuticals | SSale | −76.9K | $176.78 | −$13.6M | −37.8%126.5K after | |
| Nov 21, 2022 (view filing) | Nov 18 | 3 days | Decker Robert JController, CAO | SSale | −16.9K | $175.00 | −$2.96M | −52.2%15.5K after | |
| Nov 10, 2022 (view filing) | Nov 9 | 1 day | Wengel Kathryn EEVP, Chief GSC Officer | SSale | −16.4K | $173.42 | −$2.85M | −18.7%71.3K after | |
| Nov 8, 2022 (view filing) | Nov 4 | 4 days | Mongon ThibautExec VP, WW Chair, Consumer | SSale | −35.2K | $171.18 | −$6.03M | −46.8%40.1K after | 2 lots |
| Oct 26, 2022 (view filing) | Oct 24 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −29.3K | $171.36 | −$5.02M | −20.3%114.7K after | 25 lots |
| Oct 26, 2022 (view filing) | Oct 24 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −20.9K | $171.19 | −$3.57M | −12.7%144.0K after | 30 lots |
| Oct 26, 2022 (view filing) | Oct 24 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −13.0K | $171.22 | −$2.23M | −7.3%164.8K after | 30 lots |
| Oct 26, 2022 (view filing) | Oct 24 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −8.26K | $171.14 | −$1.41M | −4.4%179.9K after | 30 lots |
| Oct 26, 2022 (view filing) | Oct 24 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −4.26K | $171.13 | −$729.5K | −2.3%184.9K after | 30 lots |
| Oct 26, 2022 (view filing) | Oct 24 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −2.81K | $171.02 | −$481.4K | −1.5%189.8K after | 29 lots |
| Oct 26, 2022 (view filing) | Oct 24 | 2 days | Hait WilliamSee Remarks | SSale | −15.0K | $171.55 | −$2.57M | −15.8%80.2K after | 2 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −22.9K | $164.50 | −$3.76M | −16.6%114.7K after | 14 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −29.9K | $164.50 | −$4.93M | −18.0%136.2K after | 30 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −13.7K | $164.50 | −$2.25M | −7.6%167.5K after | 30 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Fasolo PeterExec VP, Chief HR Officer | SSale | −3.61K | $164.50 | −$594.3K | −2.0%181.2K after | 29 lots |
| Jun 14, 2022 (view filing) | Jun 10 | 4 days | Wengel Kathryn EEVP, Chief GSC Officer | SSale | −40.0K | $173.00 | −$6.92M | −35.9%71.3K after | 4 lots |